P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971456.29068.f6 |
| _version_ | 1827331301399592960 |
|---|---|
| author | Yan Gao Xue-Ping LI Xiao-Xiao Wang Bing Bai Xuan-Ye Zhang Su-Xia Lin Yan-Xia He LI-Qin Ping Cheng Huang Ji-Bin LI Jia-Ling Zhuang Hui-Qiang Huang |
| author_facet | Yan Gao Xue-Ping LI Xiao-Xiao Wang Bing Bai Xuan-Ye Zhang Su-Xia Lin Yan-Xia He LI-Qin Ping Cheng Huang Ji-Bin LI Jia-Ling Zhuang Hui-Qiang Huang |
| author_sort | Yan Gao |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:34:09Z |
| format | Article |
| id | doaj.art-1823f808661d4d3493cd60b7e6d80429 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:34:09Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-1823f808661d4d3493cd60b7e6d804292024-03-03T10:04:28ZengWileyHemaSphere2572-92412023-08-017e29068f610.1097/01.HS9.0000971456.29068.f6202308003-01038P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIALYan Gao0Xue-Ping LI1Xiao-Xiao Wang2Bing Bai3Xuan-Ye Zhang4Su-Xia Lin5Yan-Xia He6LI-Qin Ping7Cheng Huang8Ji-Bin LI9Jia-Ling Zhuang10Hui-Qiang Huang111 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China2 Sun Yat-Sen University Cancer Center, Department of hematology, Guangzhou, China1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China3 Sun Yat-Sen University Cancer Center, Department of pathology, Guangzhou, China4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China5 Sun Yat-Sen University Cancer Center, Department of Clinical Research, Guangzhou, China4 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, China1 Sun Yat-Sen University Cancer Center, Department of Medical Oncology, Guangzhou, Chinahttp://journals.lww.com/10.1097/01.HS9.0000971456.29068.f6 |
| spellingShingle | Yan Gao Xue-Ping LI Xiao-Xiao Wang Bing Bai Xuan-Ye Zhang Su-Xia Lin Yan-Xia He LI-Qin Ping Cheng Huang Ji-Bin LI Jia-Ling Zhuang Hui-Qiang Huang P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL HemaSphere |
| title | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_full | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_fullStr | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_full_unstemmed | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_short | P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL |
| title_sort | p1140 combination anti pd1 antibody and rituximab followed by r chop for newly diagnosed dlbcl in elderly patients analysis of the phase ii trend trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000971456.29068.f6 |
| work_keys_str_mv | AT yangao p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT xuepingli p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT xiaoxiaowang p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT bingbai p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT xuanyezhang p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT suxialin p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT yanxiahe p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT liqinping p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT chenghuang p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT jibinli p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT jialingzhuang p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial AT huiqianghuang p1140combinationantipd1antibodyandrituximabfollowedbyrchopfornewlydiagnoseddlbclinelderlypatientsanalysisofthephaseiitrendtrial |